---
title: "GLP-1 receptor agonist weight loss in breast cancer patients on endocrine therapy"
id: "pubmed-42932003"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42932003"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42932003/"
doi: "10.1007/s10549-026-08096-z"
published_at: "2026-10-26T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 receptor agonist weight loss in breast cancer patients on endocrine therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42932003
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42932003/)
- **DOI:** [10.1007/s10549-026-08096-z](https://doi.org/10.1007%2Fs10549-026-08096-z)
- **Published At:** 2026-10-26T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Retrospective cohort of 269 breast cancer patients receiving concurrent **GLP-1 receptor agonists** and adjuvant **endocrine therapy** at a single academic center. - Inclusion required GLP-1 RA initiation during the study period and at least one year of concurrent treatment; medication lists and pharmacy records were the data sources. - Primary outcome: percentage weight change from GLP-1 start to 12 months (±2 months); secondary outcomes: proportions achieving ≥5%, ≥10%, and ≥15% weight loss. - Mean one-year percentage weight loss was −4.5% (95% CI −6.0% to −3.0%); absolute mean loss −3.9 kg (95% CI −4.96 to −2.93 kg). These results were significantly lower than the 10–20% reported in postmenopausal subgroups of randomized GLP-1 trials (p < 0.001). - Only 21.3% of the cohort achieved ≥10% loss; 10.4% achieved ≥15% loss. - Weight change varied by agent (p = 0.003): **semaglutide** (−5.8%) and **tirzepatide** (−4.7%) outperformed **dulaglutide** (+0.1%), the latter approved for type 2 diabetes only. - Higher baseline weight correlated with greater absolute weight loss (r = −0.19, p = 0.002); percentage weight loss did not differ by baseline BMI category (p = 0.303). - Progesterone receptor (PR) status associated with outcomes: PR-negative patients lost more weight than PR-positive patients (−8.2% vs −4.2%; p = 0.021). - Type 2 diabetes was present in 70.6% of participants; T2DM status was not significantly associated with weight loss by t-test (p = 0.288), but non-diabetic patients were numerically more likely to reach ≥15% loss (21.5% vs 5.8%). - Study limitations reported: single-center, retrospective design; the abstract does not report dosing regimens or other detailed methodological parameters. The authors call for prospective trials given emerging oncologic evidence.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42932003/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42932003%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42932003/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42932003/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42932003/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42932003/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42932003/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42932003%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42932003%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42932003/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42932003/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42932003/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42932003/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42932003/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42932003/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42932003/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42932003/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42932003/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42932003/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42932003/#substances) Title & authors Abstract Conflict of interest statement References MeSH terms Substances Breast Cancer Res Treat Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Cancer+Res+Treat%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Breast+Cancer+Res+Treat%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) . 2026 Oct 26;220(1):17. doi: 10.1007/s10549-026-08096-z. # GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis [Keri Morgan Cronin](https://pubmed.ncbi.nlm.nih.gov/?term=Cronin+KM&cauthor_id=42932003)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42932003/#full-view-affiliation-1 "Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. keri.cronin@mountsinai.org."), [Amy Tiersten](https://pubmed.ncbi.nlm.nih.gov/?term=Tiersten+A&cauthor_id=42932003)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42932003/#full-view-affiliation-2 "Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA.") Affiliations Expand ### Affiliations * 1 Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. keri.cronin@mountsinai.org. * 2 Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. * PMID: **42932003** * DOI: [ 10.1007/s10549-026-08096-z ](https://doi.org/10.1007/s10549-026-08096-z) Item in Clipboard # GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis Keri Morgan Cronin et al. Breast Cancer Res Treat. 2026. Show details Display options Display options Format Abstract PubMed PMID Breast Cancer Res Treat Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Cancer+Res+Treat%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Breast+Cancer+Res+Treat%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) . 2026 Oct 26;220(1):17. doi: 10.1007/s10549-026-08096-z. ### Authors [Keri Morgan Cronin](https://pubmed.ncbi.nlm.nih.gov/?term=Cronin+KM&cauthor_id=42932003)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42932003/#short-view-affiliation-1 "Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. keri.cronin@mountsinai.org."), [Amy Tiersten](https://pubmed.ncbi.nlm.nih.gov/?term=Tiersten+A&cauthor_id=42932003)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42932003/#short-view-affiliation-2 "Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA.") ### Affiliations * 1 Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. keri.cronin@mountsinai.org. * 2 Department of Breast Oncology, Mount Sinai Hospital, 1468 Madison Ave, New York, NY, 10029, USA. * PMID: **42932003** * DOI: [ 10.1007/s10549-026-08096-z ](https://doi.org/10.1007/s10549-026-08096-z) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Background:** Endocrine therapy for hormone receptor-positive breast cancer is associated with adverse metabolic effects - including increased fat mass, decreased lean muscle mass, and insulin resistance - that may attenuate the efficacy of GLP-1 receptor agonists (GLP-1 RAs). This study evaluated GLP-1 RA-associated weight loss outcomes in breast cancer patients receiving concurrent endocrine therapy. **Methods:** We conducted a retrospective cohort analysis of 269 breast cancer patients at a single academic center receiving concurrent GLP-1 RA and adjuvant endocrine therapy. GLP-1 RA and endocrine therapy data were obtained from electronic medication reconciliation lists and pharmacy dispense reports. Patients were required to have initiated GLP-1 therapy during the study period and to have received concurrent GLP-1 RA and endocrine therapy for at least one year. The primary outcome was percentage weight change from GLP-1 initiation to 12 months (± 2 months). Secondary outcomes included proportions achieving ≥ 5%, ≥ 10%, and ≥ 15% weight loss. **Results:** Mean one-year percentage weight loss was - 4.5% (95% CI: -6.0% to - 3.0%; -3.9 kg; 95% CI: -4.96 to - 2.93 kg), significantly below the 10-20% observed in postmenopausal subgroups of GLP-1 randomized trials (all p < 0.001). Only 21.3% achieved ≥ 10% and 10.4% achieved ≥ 15% weight loss. Weight loss differed significantly by GLP-1 agent (p = 0.003); semaglutide (- 5.8%) and tirzepatide (- 4.7%) outperformed dulaglutide (+ 0.1%), which is approved for type 2 diabetes only. Higher baseline weight was associated with greater absolute loss (r = - 0.19, p = 0.002), though percentage weight loss did not differ significantly by baseline BMI category (p = 0.303). PR-negative patients lost more than PR-positive patients (- 8.2% vs. -4.2%; p = 0.021, d = 0.46). Type 2 diabetes was present in 70.6% of patients; T2DM status was not significantly associated with weight loss on t-test (p = 0.288), though patients without T2DM were numerically more likely to achieve ≥ 15% loss (21.5% vs. 5.8%). **Conclusions:** GLP-1 RAs produce statistically significant but substantially attenuated weight loss in breast cancer patients on concurrent endocrine therapy. GLP-1 agent selection significantly influences outcomes. Given emerging evidence of oncologic benefit, prospective trials are needed. **Keywords:** Aromatase inhibitors; Breast cancer; Endocrine therapy; GLP-1 receptor agonists; Metabolic effects; Obesity; Ovarian suppression; Tamoxifen; Type 2 diabetes; Weight loss. © 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethical approval: Not applicable. Competing interests: The authors declare no competing interests. ## References 1. 1. Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002 - [DOI](https://doi.org/10.1056/nejmoa2032183) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/33567185/) 2. 1. Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205–216 - [DOI](https://doi.org/10.1056/nejmoa2206038) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35658024/) 3. 1. Lauby-Secretan B, Scoccianti C, Loomis D et al (2016) Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med 375:794–798 - [DOI](https://doi.org/10.1056/nejmsr1606602) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/27557308/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/6754861/) 4. 1. Demark-Wahnefried W, Peterson BL, Winer EP et al (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19:2381–2389 - [DOI](https://doi.org/10.1200/jco.2001.19.9.2381) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/11331316/) 5. 1. Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12:282–294 - [DOI](https://doi.org/10.1111/j.1467-789x.2010.00805.x) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/20880127/) Show all 19 references ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Antineoplastic Agents, Hormonal* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Hormonal%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents%2C+Hormonal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Antineoplastic Agents, Hormonal* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Hormonal%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents%2C+Hormonal) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Breast Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Breast Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Glucagon-Like Peptide-1 Receptor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Glucagon-Like Peptide-1 Receptor Agonists* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor+Agonists) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Glucagon-Like Peptides / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptides%2Fadministration+and+dosage%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptides) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Glucagon-Like Peptides / analogs & derivatives Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptides%2Fanalogs+and+derivatives%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptides) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Glucagon-Like Peptides / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptides%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptides) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Immunoglobulin Fc Fragments / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoglobulin+Fc+Fragments%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoglobulin+Fc+Fragments) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Middle Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Recombinant Fusion Proteins / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Recombinant+Fusion+Proteins%2Fadministration+and+dosage%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Recombinant+Fusion+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Recombinant Fusion Proteins / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Recombinant+Fusion+Proteins%2Fadverse+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Recombinant+Fusion+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Recombinant Fusion Proteins / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Recombinant+Fusion+Proteins%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Recombinant+Fusion+Proteins) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42932003/) * Retrospective Studies Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Retr
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Resistance exercise preserves lean mass during tirzepatide therapy for obesity](https://medichelpline.com/clinical-feed/nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for.md)
- [Tirzepatide in Older Adults with Type 2 Diabetes: Real-World Hypoglycemia and Weight Outcomes](https://medichelpline.com/clinical-feed/pubmed-42457543.md) (DOI: 10.1507/endocrj.EJ26-0246)
- [Semaglutide preserves kidney function in type 2 diabetes: mechanisms from the REMODEL randomized t](https://medichelpline.com/clinical-feed/nature-1-effects-of-semaglutide-on-kidney-disease-in-type-2-diabetes-a-randomized.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.